ClinicalTrials.gg
RecruitingNCT06158854Updated May 13, 2026

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

A Phase 1/2 interventional study of ABBV-383 (Etentamig) in Immunoglobulin Light Chain (AL) Amyloidosis, sponsored by AbbVie. Recruiting at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.

Planned enrollment
42nd of 99
76 · median 45
Started
2024
with 6 others
Phase 1/2
12 of 141
4 open now
Primary completion
2028-02
later than 31 of 46 live
Registered
118th of 141
by date

Among the 141 studies in Amyloidosis with a site in United States, this one is the 42nd largest by planned enrollment of the 99 interventional ones that give a count, is one of 7 that started in 2024, is one of 12 in phase 1/2, reaches primary completion later than 31 of the 46 other live ones, and was the 118th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Amyloidosis with a site in United States, or all of them as a file.
02

Study summary

Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383.

Etentamig (ABBV-383) is an investigational drug being developed for the treatment of AL amyloidosis. This study in broken into 2 parts (dose escalation and dose expansion) with 4 arms. During dose escalation (arms 1-3) participants will receive 1 of 3 doses of ABBV-383 to determine the part 2 dose. After completion of the dose escalation portion of the study, the dose expansion (part 2) portion of the study will begin. One arm (arm 4) will begin and participants will receive a dose determined during the dose escalation portion (part 1). Around 76 adult participants with relapsed/refractory AL amyloidosis will be enrolled at approximately 25 sites across the world.

Participants will receive Etentamig (ABBV-383) as an infusion into the vein for up to approximately 2 year study duration.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

03

Conditions studied

  • Immunoglobulin Light Chain (AL) Amyloidosis

Browse trials for

Keywords

  • Immunoglobulin Light Chain (AL) Amyloidosis
  • ABBV-383
  • TNB-383B
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary systemic immunoglobulin light chain (AL) amyloidosis.
  • (ECOG) performance status of \<= 2.
  • Have at least 1 organ historically impacted by AL amyloidosis.
  • Considered AL amyloidosis cardiac risk stage 1, 2, or 3a, or considered risk stage 3b with stable cardiac function and markers for 3 months prior to dosing, and have of AL amyloidosis as defined by difference between involved and uninvolved free light chains (dFLC) >= 50 mg/L or meeting high-risk dFLC progression criteria after immediate .
  • Has previously been exposed to a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.

Exclusion criteria

Exclusion Criteria:

  • Known history of (per investigator's judgment) drug or alcohol abuse within the last 6 months.
  • Known allergic reaction, significant sensitivity, or intolerance to constituents of the study treatment (and ) and/or other products in the same class.
  • Participant has the following conditions:

    • Other non-AL amyloid disease;
    • Previous or current diagnosis of symptomatic multiple myeloma (MM), including the presence of lytic bone disease, plasmacytomas, >= 60% plasma cells in the bone marrow, or hypercalcemia (defined as corrected calcium > 11 mg/dL);
    • Active plasma cell leukemia (i.e., either 20% of peripheral white blood cells or > 2.0 × 109/L circulating plasma cells by standard differential);
    • Waldenström's macroglobulinemia;
    • Acute diffuse infiltrative pneumopathy;
    • Major surgery within 28 days prior first dose or planned during study participation;
    • History of organ transplant requiring continued use of ;
    • Acute infections within 14 days prior first dose requiring parenteral therapy (antibiotic, antifungal, or antiviral);
    • Participant has received an stem cell transplant (SCT) within 12 weeks or an allogeneic SCT within 1 year of the first dose of study treatments.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Dose Escalation: ABBV-383 (etentamig) Dose A

    Participants will receive ABBV-383 (etentamig) dose A during the approximately 2 year study duration.

    Drug: ABBV-383 (Etentamig)

  • Experimental
    Dose Escalation: ABBV-383 (etentamig) Dose B

    Participants will receive ABBV-383 (etentamig) dose B during the approximately 2 year study duration.

    Drug: ABBV-383 (Etentamig)

  • Experimental
    Dose Escalation: ABBV-383 (etentamig) Dose C

    Participants will receive ABBV-383 (etentamig) dose C during the approximately 2 year study duration.

    Drug: ABBV-383 (Etentamig)

  • Experimental
    Dose Expansion: ABBV-383 (etentamig)

    Participants will receive ABBV-383 (etentamig) expansion dose B during the approximately 2 year study duration.

    Drug: ABBV-383 (Etentamig)

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation Only: Number of Participants with Dose-Limiting Toxicities (DLT)

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to 28 Days

  2. Dose Expansion Only: Percentage of Participants who Achieve Hematologic Complete Response (CR)

    Hematologic CR is defined as the percentage of participants who achieve normalization of free light chain levels, negative serum immunofixation, negative urine immunofixation as determined per the modified International Amyloidosis Consensus Criteria (IACC).

    Time frame: Up to 4 years

  3. Dose Expansion Only: Number of Participants with DLTs

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to 4 years

  4. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 4 years

Secondary outcomes

  1. Hematologic Overall Response Rate (ORR)

    Hematologic ORR is defined as partial response (PR) + very good partial response (VGPR) + complete remission (CR), proportion of participants who achieved a PR or better, per the modified IACC.

    Time frame: Up to 4 Years

  2. Time to Hematologic CR

    Time to hematologic CR is defined as the time from first dose of study drug until CR, per the modified IACC.

    Time frame: Up to 4 Years

  3. Duration of Hematologic CR

    Duration of hematologic CR is defined as the time from CR until disease progression, per the modified IACC.

    Time frame: Up to 4 Years

  4. Organ Response Rate (OrRR)

    Organ response rate is defined as the time from first dose of study drug until to response in the heart kidney and liver, per the IACC.

    Time frame: Up to 4 Years

  5. Time to Organ Response

    Time to organ response is defined as the time from first dose of study drug until organ response, per the IACC.

    Time frame: Up to 4 Years

  6. Dose Escalation Only: Percentage of Participants who Achieve Hematologic CR Rate as Determined

    Hematologic CR is defined as the percentage of participants who achieve normalization of free light chain levels, negative serum immunofixation, negative urine immunofixation as determined per the modified International Amyloidosis Consensus Criteria (IACC).

    Time frame: Up to 4 years

07

Study locations

23 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Feb 2028, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2023
First posted
Dec 6, 2023
StartActual
Apr 1, 2024
Primary completionEst.
Feb 2028
CompletionEst.
Aug 2031
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06158854
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 6, 2023
Start date
Apr 1, 2024
Primary completion
Feb 2028 (estimated)
Completion
Aug 2031 (estimated)
Last update
May 13, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etentamig

Start the discussion